Skip to content

US · SOPH · MEDICAL - HEALTHCARE INFORMATION SERVICES

SOPHiA GENETICS S.A. (SOPH) intrinsic value and stock valuation

$6.23as of 2026-11-21 · Mkt cap 439.2M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

SOPHiA GENETICS S.A. DCF and intrinsic value

InvestorsCraft values SOPH with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SOPH’s statements →

SOPHiA GENETICS S.A. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services Rolle, VD 1180 sophiagenetics.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$77.3M+22.2% 5y CAGRd
20192025
Net income
-$-79M
20192025
Free cash flow
-$-38.59M
20192025
Total equity
$47.2M-14% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$77.3M$65.2M$62.4M$47.6M$40.5M
Operating income-$-70.92M-$-66.57M-$-74.83M-$-87.82M-$-71.49M
Net income-$-79M-$-62.49M-$-78.98M-$-87.45M-$-73.67M
EPSd-$-1.17M-$-949.98K-$-1.22M-$-1.36M-$-1.33M
Operating cash flow-$-38.01M-$-42.82M-$-48.58M-$-70.09M-$-57.94M
Capital expenditure-$-570K-$-8.18M-$-9.23M-$-10.38M-$-6.67M
Free cash flow-$-38.59M-$-51M-$-57.8M-$-80.47M-$-64.61M
Total assets$163.5M$155.3M$206.2M$243.8M$320.2M
Total debt$63M$30M$18.6M$16.7M$13.1M
Net debt-$-7.27M-$-50.2M-$-104.65M-$-144.56M-$-179.9M
Total equity$47.2M$96.5M$151.4M$200.1M$275.4M
Cash and short-term investments$70.3M$80.2M$123.3M$178.6M$265.3M
Income statement
20252024202320222021
Revenue$77.3M$65.2M$62.4M$47.6M$40.5M
Cost of revenue$29.5M$21.2M$19.5M$16.3M$15.2M
Gross profit$47.8M$43.9M$42.9M$31.3M$25.2M
Research and development expenses$33.6M$34.4M$37M$35.4M$26.6M
Selling, general and administrative expenses$85.2M$76.3M$81.7M$84.1M$70.2M
Other expenses$0.00-$-180K-$-950K-$-380K-$-110K
Operating expenses$118.7M$110.5M$117.7M$119.1M$96.7M
Cost and expenses$148.2M$131.7M$137.2M$135.4M$111.9M
Interest income$1.87M$3.36M$4.55M$1.32M$20K
Interest expense$4.55M$1.91M$590K$640K$660K
Depreciation and amortization$9.53M$8.6M$8.34M$5.57M$3.61M
Ebitda-$-64.4M-$-50.76M-$-69.57M-$-81.38M-$-69.24M
Operating income-$-70.92M-$-66.57M-$-74.83M-$-87.82M-$-71.49M
Total other income/expenses, net-$-7.56M$5.3M-$-3.67M$240K-$-2.02M
Income before tax-$-78.49M-$-61.27M-$-78.5M-$-87.58M-$-73.51M
Income tax expense$510K$1.22M$490K-$-140K$170K
Net income-$-79M-$-62.49M-$-78.98M-$-87.45M-$-73.67M
Weighted average shares outstanding$67.5M$65.8M$64.8M$64.1M$55.3M
Weighted average diluted shares outstanding$67.5M$65.8M$64.8M$64.1M$55.3M
Balance sheet
20252024202320222021
Cash and short-term investments$70.3M$80.2M$123.3M$178.6M$265.3M
Net receivables$18.5M$8.69M$15.2M$8.05M$7.09M
Inventory$6.35M$5.87M$6.48M$5.16M$5.73M
Total current assets$99.1M$99.4M$148.1M$196.3M$282.9M
Property, plant and equipment, net$18.1M$19.4M$23.1M$21.4M$16M
Goodwill and intangible assets$35.9M$29M$27.2M$20M$15.7M
Long-term investments$1.98M$0.00$0.00$0.00$0.00
Total non-current assets$64.4M$55.9M$58.1M$47.6M$37.3M
Total assets$163.5M$155.3M$206.2M$243.8M$320.2M
Accounts payable$5.32M$1.93M$2.26M$2.17M$2.34M
Short-term debt$2.7M$2.19M$2.93M$2.69M$1.81M
Deferred revenue$16.7M$5.73M$9.49M$3.43M$4.07M
Total current liabilities$50.5M$26.8M$35.6M$26.8M$28.6M
Long-term debt$60.3M$27.8M$15.7M$14.1M$11.3M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$65.8M$32M$19.1M$16.9M$16.2M
Capital lease obligations$15.3M$16.8M$18.6M$16.7M$13.1M
Total liabilities$116.3M$58.8M$54.7M$43.7M$44.8M
Common stock$4.81M$4.19M$4.05M$3.46M$3.33M
Retained earnings-$-519.28M-$-440.28M-$-377.78M-$-298.8M-$-211.35M
Accumulated other comprehensive income (loss)$89.2M$61M$54M$24M$12.5M
Total equity$47.2M$96.5M$151.4M$200.1M$275.4M
Total investments$1.98M$0.00$0.00$17.3M$72.4M
Total debt$63M$30M$18.6M$16.7M$13.1M
Net debt-$-7.27M-$-50.2M-$-104.65M-$-144.56M-$-179.9M
Cash flow statement
20252024202320222021
Net income-$-79M-$-61.27M-$-78.5M-$-87.58M-$-73.51M
Depreciation and amortization$9.53M$8.6M$8.34M$5.57M$3.61M
Stock-based compensation$0.00$16.5M$15.2M$13.6M$8.51M
Change in working capital$10.7M-$-2.58M$870K-$-1.27M$6.12M
Accounts receivable-$-6.6M$5.89M-$-6.5M$1.33M$1.81M
Inventory$50K$70K-$-870K-$-200K-$-2.34M
Accounts payable$16.9M-$-7.38M$6.87M-$-1.43M$8.98M
Net cash provided by operating activities-$-38.01M-$-42.82M-$-48.58M-$-70.09M-$-57.94M
Investments in property, plant and equipment-$-8.62M-$-240K-$-1.49M-$-4.1M-$-6.67M
Acquisitions, net$0.00$0.00$0.00$0.00$3.99M
Net cash used for investing activities-$-10.51M-$-8.18M$8.32M$42M-$-56.93M
Common stock issued$1.44M$410K$0.00$0.00$231.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$34.1M$11.6M-$-2.82M-$-1.57M$237.8M
Net change in cash-$-9.94M-$-43.02M-$-38.05M-$-31.66M$118.3M
Cash at end of period$70.3M$80.2M$123.3M$161.3M$193M
Operating cash flow-$-38.01M-$-42.82M-$-48.58M-$-70.09M-$-57.94M
Capital expenditure-$-570K-$-8.18M-$-9.23M-$-10.38M-$-6.67M
Free cash flow-$-38.59M-$-51M-$-57.8M-$-80.47M-$-64.61M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About SOPHiA GENETICS S.A.

        SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe. Founded in 2011, SOPHiA GENETICS S.A. is headquartered in Saint-Sulpice, Switzerland.

        CEO
        Ross Muken
        Employees
        415
        Beta
        0.96

        Explore

        Frequently asked questions

        What is the intrinsic value of SOPHiA GENETICS S.A. (SOPH)?

        SOPHiA GENETICS S.A. (SOPH) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SOPH undervalued?

        SOPH trades at a price of $6.23 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.